Ipamorelin – 10mg (3ml Pen)

Ipamorelin 10mg (3ml Pen) – Selective Growth Hormone Secretagogue Research Peptide

Ipamorelin is a synthetic pentapeptide investigated for its selective growth hormone-releasing activity, ghrelin receptor interactions and endocrine signalling. Developed as part of research into growth hormone secretagogues, Ipamorelin is distinguished by its ability to stimulate growth hormone secretion with comparatively limited effects on certain additional pituitary and adrenal hormones in preclinical studies.

Unlike conventional growth hormone-releasing hormone (GHRH) analogues, Ipamorelin acts primarily through the growth hormone secretagogue receptor GHS-R1a.

This distinctive receptor activity makes Ipamorelin relevant to scientific investigations into pituitary function, hormonal selectivity, growth hormone regulation and biological pathways associated with muscle physiology.

Available in a 10mg, 3ml pen format, Ipamorelin forms part of the Coridion Sciences research peptide range.

What Is Ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide developed to investigate whether growth hormone secretion could be stimulated with greater endocrine selectivity than earlier growth hormone-releasing peptides.

Compounds such as GHRP-2 and GHRP-6 have demonstrated growth hormone secretagogue activity but can also influence other hormones, including ACTH and cortisol.

In comparative preclinical research, Ipamorelin demonstrated substantial growth hormone-releasing activity without similarly pronounced ACTH or cortisol responses.

This selectivity is one of the compound’s defining pharmacological characteristics.

However, these findings should not be interpreted as evidence that Ipamorelin is free from adverse effects or that its hormonal selectivity has been established across all human populations.

Ipamorelin and Muscle Growth Research

Growth hormone contributes to multiple physiological processes involving skeletal muscle, protein metabolism, tissue development and energy regulation.

Ipamorelin is investigated for its ability to stimulate endogenous growth hormone secretion through ghrelin receptor activation.

Researchers examining growth hormone-related mechanisms may investigate:

• Growth hormone secretion: Receptor-mediated stimulation of pituitary growth hormone release.
• Muscle physiology: Endocrine pathways involved in protein metabolism and skeletal muscle regulation.
• IGF-1 signalling: The relationship between growth hormone activity and downstream insulin-like growth factor pathways.
• Tissue metabolism: Hormonal mechanisms influencing cellular development and protein turnover.
• Endocrine selectivity: Differences between growth hormone responses and other pituitary or adrenal hormone activity.
• Metabolic regulation: Interactions between growth hormone signalling and energy metabolism.

Although these processes are relevant to muscle physiology, clinical evidence does not establish that Ipamorelin directly improves muscle growth, strength, recovery or athletic performance in humans.

Researchers investigating related compounds can explore our wider collection of peptides for muscle development and growth hormone research, featuring compounds studied for endocrine regulation, tissue physiology and growth-related signalling mechanisms.

Mechanism of Action: How Does Ipamorelin Work?

GHS-R1a Receptor Activation

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor GHS-R1a, commonly called the ghrelin receptor.

Activation of this receptor initiates intracellular signalling pathways associated with pituitary growth hormone secretion.

These mechanisms differ from GHRH receptor signalling, which primarily involves cyclic AMP-mediated activity.

Pituitary Growth Hormone Release

Experimental studies have demonstrated that Ipamorelin stimulates growth hormone secretion through growth hormone secretagogue receptor activity.

Its effects have been investigated using isolated pituitary cells and animal models.

The magnitude of the growth hormone response depends on experimental conditions, physiological state and other endocrine influences.

Hormonal Selectivity

One of Ipamorelin’s defining research characteristics is its comparatively selective endocrine response.

A frequently cited 1998 study found that Ipamorelin stimulated growth hormone secretion without significantly increasing ACTH or cortisol beyond the responses observed with GHRH stimulation in the experimental models used.

This contrasted with GHRP-2 and GHRP-6, which produced additional hormonal responses under comparable experimental conditions.

These findings provide an important basis for studying receptor selectivity but do not establish complete hormonal specificity or clinical safety in humans.

Growth Hormone and IGF-1 Pathways

Growth hormone influences insulin-like growth factor-1 (IGF-1) signalling, which participates in tissue growth and cellular regulation.

Ipamorelin research provides a model for investigating the upstream receptor mechanisms controlling growth hormone release.

However, the downstream physiological effects of Ipamorelin cannot be assumed to match those of directly administered growth hormone.

Scientific Research Applications

1. Selective Growth Hormone Secretion

Ipamorelin is of particular interest in studies examining whether growth hormone secretion can be stimulated without equally pronounced activation of other endocrine pathways.

This characteristic helps distinguish it from earlier growth hormone-releasing peptides.

2. Ghrelin Receptor Pharmacology

The growth hormone secretagogue receptor participates in several biological processes, including hormonal regulation and appetite-related signalling.

Ipamorelin provides a research compound for investigating receptor activation, intracellular signalling and endocrine responses.

3. Pituitary Function Research

Research involving Ipamorelin has examined growth hormone secretion from pituitary cells and whole-animal experimental models.

These studies contribute to understanding the regulation of growth hormone release.

4. Combination Research with GHRH Analogues

Growth hormone secretagogues and GHRH analogues act through different receptor pathways.

Research into simultaneous receptor activation has demonstrated that these mechanisms can interact to influence growth hormone secretion.

However, evidence concerning other peptide combinations should not automatically be applied to every Ipamorelin formulation.

5. Gastrointestinal Motility

Experimental investigations have examined Ipamorelin and related ghrelin receptor agonists in gastrointestinal motility research.

These studies include models investigating gastric emptying and postoperative gastrointestinal dysfunction.

Results remain dependent on the experimental model and do not establish an approved therapeutic application for Ipamorelin.

6. Bone and Tissue Physiology

Preclinical research has explored the relationship between growth hormone secretagogue activity and skeletal physiology.

Some experimental investigations have examined bone-related outcomes, although evidence remains insufficient to establish clinical benefits for bone density, tissue repair or musculoskeletal recovery.

Ipamorelin Compared with Other Growth Hormone Secretagogues

Ipamorelin belongs to the same broad research class as GHRP-2, GHRP-6 and Hexarelin, but its pharmacological profile differs in several important respects.

Ipamorelin

A synthetic pentapeptide investigated for comparatively selective growth hormone secretion and limited ACTH and cortisol responses in preclinical models.

GHRP-2

Investigated for strong growth hormone secretagogue activity and additional endocrine responses involving ACTH and cortisol.

GHRP-6

Studied for growth hormone secretion, ghrelin receptor activation and appetite-related biological signalling.

Hexarelin

Investigated for potent growth hormone secretagogue activity, receptor desensitisation and cardiovascular research mechanisms.

CJC-1295 No DAC

A GHRH analogue that stimulates growth hormone release through a separate receptor system, making it relevant to research into complementary endocrine pathways.

Understanding these differences allows researchers to distinguish compounds according to their receptor pharmacology and experimental applications.

Ipamorelin 10mg Product Specifications

• Product: Ipamorelin
• Quantity: 10mg
• Format: 3ml pen
• Classification: Synthetic growth hormone secretagogue
• Peptide structure: Pentapeptide
• Primary receptor: GHS-R1a
• Primary research focus: Selective growth hormone secretion and endocrine signalling
• Additional research areas: Muscle physiology, pituitary function, receptor pharmacology and metabolic regulation
• Research status: Investigational compound

Ipamorelin Research from Coridion Sciences

Coridion Sciences supplies specialist research peptides and advanced peptide formulations for scientific and laboratory investigation.

Its research catalogue includes individual compounds and peptide combinations investigated across growth hormone regulation, endocrine signalling, cellular processes and metabolic physiology.

Ipamorelin 10mg is supplied in a 3ml pen format as part of the company’s growth hormone secretagogue research range.

Research Use Only: Ipamorelin is intended exclusively for scientific and laboratory research. It is not approved for human consumption, medical treatment, muscle-building therapy or athletic performance enhancement.

Ipamorelin is a synthetic pentapeptide acting as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor. Research describes growth hormone release through a pathway distinct from GHRH signalling, involving suppression of somatostatin tone alongside direct somatotroph stimulation. The defining finding across the literature is selectivity: studies consistently report growth hormone release without meaningful elevation of cortisol, ACTH or prolactin at comparable levels, distinguishing it from GHRP-6 and hexarelin.

A solid preclinical and early clinical literature, with selectivity relative to other ghrelin receptor agonists the most consistently replicated finding.

Receptor selectivity

Comparative studies reporting minimal cortisol, ACTH and prolactin involvement.

Secretagogue pharmacology

Characterisation of GHS-R1a agonism and somatostatin tone suppression.

Combination research

Work documenting synergistic release when paired with GHRH analogues.

Gastrointestinal motility

Studies on postoperative ileus models exploring ghrelin receptor effects.

Bone research

Preclinical investigation of bone mineral density endpoints in rodent models.